We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novartis Boosts Cell Therapy Portfolio in Licensing, R&D Deal
Novartis Boosts Cell Therapy Portfolio in Licensing, R&D Deal
September 13, 2013
Looking to pump up its cell therapy portfolio, Novartis Sept. 6 revealed plans to partner with Kentucky-based Regenerex for use of the company’s facilitating cell therapy (FCRx) platform.